PMID- 25693082
OWN - NLM
STAT- MEDLINE
DCOM- 20150707
LR  - 20191113
IS  - 1233-9687 (Print)
IS  - 1233-9687 (Linking)
VI  - 65
IP  - 4
DP  - 2014 Dec
TI  - Topoisomerase 2alpha status in invasive breast carcinoma - comparison of its clinical 
      value according to immunohistochemical and fluorescence in situ hybridization 
      methods of evaluation.
PG  - 283-90
AB  - The main purpose of the study was to compare topoisomerase 2alpha (TOP2A) status in 
      invasive breast carcinomas to the outcome of a therapy containing neoadjuvant 
      treatment with anthracyclines (a combination chemotherapy treatment for breast 
      cancer, namely AC [cyclophosphamide, doxorubicin]). To achieve these goals we 
      created a method of evaluation with criteria based on two methods used in the 
      present study (immunohistochemical [IHC] and fluorescence in situ hybridization 
      [FISH]). The threshold for positive immunohistochemically evaluated status was 
      set for all cases with: nuclear stain intensity score 3+ in 10% or more nuclei 
      and nuclear stain intensity score 2+ in 50% or more nuclei. Our results suggest 
      that TOP2A status may be used as a predictive factor for patient selection for 
      protocols which include anthracyclines as one of the chemotherapeutics. Both 
      methods, IHC and FISH, are suitable for implementation for diagnostic purposes, 
      but IHC positive status measured according to the criteria presented above is the 
      best predictor of longer disease-free survival (DFS) according to our study. 
      Immunohistochemical also gave satisfactory results in all analyzed cases in 
      comparison to only 60% of cases analyzed by FISH.
FAU - Olszewski, Wt
AU  - Olszewski W
FAU - Pienkowski, T
AU  - Pienkowski T
FAU - Olszewski, Wp
AU  - Olszewski W
AD  - Wojciech P. Olszewski, MD, PhD, Department of Pathology, Maria Sklodowska-Curie 
      Cancer Center, Roentgena 5, 02-781 Warsaw, Poland, e-mail: wppo@o2.pl.
FAU - Mrozkowiak, A
AU  - Mrozkowiak A
FAU - Bauer-Kosinska, B
AU  - Bauer-Kosinska B
FAU - Piascik, A
AU  - Piascik A
FAU - Olszewska, K
AU  - Olszewska K
FAU - Wojnowska, A
AU  - Wojnowska A
FAU - Michalski, W
AU  - Michalski W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Pol J Pathol
JT  - Polish journal of pathology : official journal of the Polish Society of 
      Pathologists
JID - 9437432
RN  - 0 (Anthracyclines)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
MH  - Anthracyclines/*therapeutic use
MH  - Antigens, Neoplasm/*metabolism
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/drug therapy/*enzymology
MH  - Carcinoma, Ductal, Breast/drug therapy/*enzymology
MH  - Chemotherapy, Adjuvant
MH  - DNA Topoisomerases, Type II/*metabolism
MH  - DNA-Binding Proteins/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Poly-ADP-Ribose Binding Proteins
EDAT- 2015/02/19 06:00
MHDA- 2015/07/08 06:00
CRDT- 2015/02/19 06:00
PHST- 2015/02/19 06:00 [entrez]
PHST- 2015/02/19 06:00 [pubmed]
PHST- 2015/07/08 06:00 [medline]
AID - 24350 [pii]
AID - 10.5114/pjp.2014.48189 [doi]
PST - ppublish
SO  - Pol J Pathol. 2014 Dec;65(4):283-90. doi: 10.5114/pjp.2014.48189.